Crescent Biopharma (CBIO) Jefferies Global Healthcare Conference 2026 summary

Key clinical data and validation

• HARMONi-6 data showed strong PFS (hazard ratio 0.6) and OS (hazard ratio 0.66) benefits, with efficacy across all PD-L1 subgroups and a favorable safety profile compared to prior standards.

• Safety data for PD-1/VEGF combinations were comparable to previous ESMO results, with no major differences in Grade 3+ events between arms.

• The class of PD-1/VEGF bispecifics is now considered validated, with landmark data supporting a paradigm shift from first-generation PD-1s.

• Data from multiple tumor types, including non-small cell lung cancer, reinforce the broad applicability of these therapies.

• Ongoing and upcoming trials (e.g., CR-001 ASCEND) will further inform optimal combinations and tumor types.

Lessons for trial design and strategy

• Trial design is critical, with emphasis on appropriate inclusion/exclusion criteria, stratification factors, and benchmarking for comparator arms.

• Age-related differences in outcomes are likely due to tumor characteristics rather than age itself; future studies will stratify by tumor size and brain metastases.

• Powering studies for OS rather than PFS is prioritized, as OS is the key regulatory endpoint and better reflects long-term benefit.

• Regional differences in control arm performance and patient populations must be considered in global trials.

• Data maturity and timing of analyses are crucial for demonstrating efficacy and safety.

Pipeline development and partnerships

• CR-001 is positioned as a best-in-class backbone therapy, with data expected across monotherapy, chemo combinations, and ADC combinations within the next year.

• Partnership with Kelun-Biotech enables access to multiple ADCs and collaborative data generation, with potential for expanded asset licensing.

• The integrin beta 6 ADC program is advancing, with learnings from Pfizer's recent strategic decisions and ongoing data readouts.

• The company aims to leverage its assets and partnerships to generate capital and establish a leadership position in next-generation immuno-oncology.

• Safety and combinability across agents are central to the backbone therapy strategy.